Enhanced efficacy in anti-tumour activity by combined therapy of recombinant FGFR-1 related angiogenesis and low-dose cytotoxic agent

European Journal of Cancer

Volumn 43, Issue 14, 2007, Pages 2134-2139

  Zheng, S P ^a,b   Zheng, S J ^a,b   Wu, R L ^b   Huang, F Y ^a   Cao, L M ^b   Jiao, C L ^a  

^a Affiliated Hospital   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Biotherapy; Chemotherapy; Fibroblast growth factor receptor 1; Gemcitabine; Tumour angiogenesis; Vaccine

Indexed keywords

AUTOANTIBODY; CANCER VACCINE; CFR 1 VACCINE; CYTOTOXIC AGENT; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GEMCITABINE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER; CANCER MODEL; CELL PROLIFERATION; CHICKEN; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOIMMUNITY; CANCER VACCINES; DEOXYCYTIDINE; DRUG SYNERGISM; FEMALE; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECOMBINANT PROTEINS;

EID: 34548502696     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.07.014     Document Type: Article

References (27)

1. Folkman J. Angiogenesis-dependent diseases. Semin Oncol 28 (2001) 536-542
2. Kerbel R.S. Tumor angiogenesis: past, present and the future. Careinogenesis 21 (2002) 505-515
3. Fan T.P., Jaggar R., and Bicknell R. Controlling the vasculature: angiogenesis anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 16 (1995) 57-66
4. Powers C.J., Mcleskey S.W., and Wellstein A. Fibroblast growth factors, their receptors and signaling. Endoc Relat Cancer 7 (2000) 165-197
5. Klint P., and Claesson-Welsh L. Signal transduction by fibroblast growth factor receptors. Front Biosci 15 (1999) 165-177
6. Chaudhuri M.M., Moscatelli D., and Basilico C. Involvement of the conserved acidic amino acid domain of FGF receptor 1 in ligand-receptor interactions. J Cell Physiol 157 (1993) 209-216
7. Cross M.J., Lu L., Magnusson P., et al. The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells. Mol Biol Cell 13 (2002) 2881-2893
8. Udayakumar T.S., Klein R.D., Maliner M.S., Nagle R.B., and Bowden G.T. Aberrant expression of fibroblast growth factor receptor-1 in prostate epithelial cells allows induction of promatrilysin expression by fibroblast growth factors. Int J Cancer 91 (2001) 187-192
9. Valesky M., Spang A.J., Fisher G.W., Farkas D.L., and Becker D. Noninvasive dynamic fluorescence Imaging of human melanomas reveals that targeted Inhibition of bFGF or FGFR-1 in melanoma cells blocks tumor growth by apoptosis. Mol Med 8 (2002) 103-111
10. Wang F., McKeehan K., Yu C.D., and McKeehan W.L. Fibroblast growth factor receptor 1 phosphotyrosine 766 molecular target for prevention of progression of prostate tumors to malignancy. Cancer Res 62 (2002) 1898-1903
11. Zheng S.J., Huang F.Y., Zheng S.P., Wang W., Yin H., and Wu R.L. Vaccination with a recombinant chicken FGFR-1 bypasses immunological tolerance against self-FGFR-1 in mice. J Huazhong Univ Sci Technolog Med Sci 26 (2006) 389-391
12. Zheng S.P., Zhang J.Z., Zheng S.J., et al. Anti-angiogeneic target therapy for cancer with vaccine based on the recombinant chicken FGFR-1 in tumor-bearing mice. J Huazhong Univ Sci Technolog Med Sci 27 (2007) 120-123
13. Prewett M., Huber J., Li Y.W., et al. Antivascular endothelial growth factor receptor (Fetal Liver Kinase 1) monoclonal anti-body inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59 (1999) 5209-5218
14. Holash J., Maisonpierre P.C., Compton D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284 (1999) 1994-1998
15. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 (2000) 1878-1886
16. Kruczynski A., Poli M., Dossi R., et al. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer 42 (2006) 2821-2832
17. Bello L., Carrabba G., Giussani C., et al. Low-dose chemotherapy combined with an anti-angiogenic drug reduces human glioma growth in vivo. Cancer Res 61 (2001) 7501-7506
18. Dings R.P.M., Yokoyama Y., Ramakrishnan S., Griffioen A.W., and Mayo K.H. The designed angiostatic peptide anginex synergistically improves chemotherapy and anti-angiogenesis therapy with angiostatin. Cancer Res 63 (2003) 382-385
19. Bruns C.J., Shrader M., Harbison M.T., et al. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 102 (2002) 101-108
20. Hertel L.W., Boder G.B., Kroin J.S., et al. Evaluation of the anticancer activity of gemcitabine (2-2-difluoro-2-deoxycytidine). Cancer Res 50 (1990) 4417-4422
21. Van Moorsel C.J.A., Peters G.J., and Pinedo H.M. Gemcitabine: Future prospects of single-agent and combination studies. The Oncologist 2 (1997) 127-134
22. Van Moorsel C.J.A., Pinedo H.M., Veerman G., Vermorken J.B., Postmus P.E., and Peters G.J. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur J Cancer 35 (1999) 808-814
23. Wild R., Ramakrishnan S., Sedgewick J., and Griffioen A.W. Quantitative assessment of angiogenesis and tumor vessel architecture by computerassisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc Res 59 (2000) 368-376
24. Dings R.P.M., Yokoyama Y., Ramakrishnan S., Griffioen A.W., and Mayo K.H. The designed angiostatic peptide anginex synergistically improves chemotherapy and anti-angiogenesis therapy with angiostatin. Cancer Res 63 (2003) 382-385
25. Huang P., and Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol 22 (1995) 19-25
26. Davidson J.D., Ma L., Flagella M., et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 64 (2004) 3761-3766
27. Smith B.D., and Judith E. Ribonucleotide reductase: an old target with new potential. Leukemia Res 27 (2003) 1075-1076